RxDoctor Payments Data

Martin Hiriart, MD

Internal Medicine · Miami, FLNPI 1235155003

Payments from drug & device makers

$3,261in general payments, 2019–2025

Across 180 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • GSK$437
  • Lilly USA, LLC$409
  • Pfizer$314
  • Boehringer Ingelheim$247
  • AstraZeneca$246
  • plus $394 from 12 others

What the payments were for

  • Food & beverage$3,249100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,261 in reported general payments places this provider in the 80th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$71,302
Medicare patients
209
Services billed
536

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide196$199,546
EliquisApixaban145$126,171
ProliaDenosumab54$92,244
JardianceEmpagliflozin81$76,998
MounjaroTirzepatide64$73,195
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$53,316
TriumeqAbacavir/Dolutegravir/Lamivudi12$51,105
FarxigaDapagliflozin Propanediol59$44,774
TradjentaLinagliptin57$41,186
TrulicityDulaglutide31$33,012
XareltoRivaroxaban19$30,536
MyrbetriqMirabegron29$28,246
Repatha SyringeEvolocumab29$25,009
LinzessLinaclotide23$19,261
GlyxambiEmpagliflozin/Linagliptin20$16,960

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,213$214,832207 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$247$135,145158 claims
PfizerEliquis$314$126,171145 claims
Lilly USA, LLCMounjaro, Trulicity$409$106,20795 claims
AmgenProlia$97$92,24454 claims
GSKTrelegy Ellipta, Breo Ellipta, Lamictal$437$70,41296 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$246$58,83784 claims
AbbVieLinzess, Synthroid$72$29,881110 claims
NovartisEntresto$19$9,15411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →